U.S., Feb. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07436416) titled 'Circulating and Urinary Exosomal miRNA as Predictors of Treatment Response in Advanced Kidney Cancer' on Feb. 12.
Brief Summary: This study investigates the role of circulating and urinary exosomal microRNAs (miRNAs) as potential biomarkers for predicting response to systemic therapy in patients with advanced renal cell carcinoma. Patients receiving immune checkpoint inhibitors or targeted therapies are followed during the first 16 weeks of treatment. Blood and urine samples are collected at predefined time points for analysis of exosome-associated miRNAs. Imaging assessments are performed as part of routine clinical follow-up. The ...